Use of clopidogrel in the reduction of myocardial damage during percutaneous coronary intervention

References

• SheldonWCTrends in cardiac catheterization laboratories in the United StatesCatheter Cardiovasc Interv2001531404511329216
   PubMedGoogle Scholar
• BhattDLTopolEJDoes creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomesCirculation20051126906915discussion 923.16087811
   PubMedGoogle Scholar
• ThygesenKAlpertJSWhiteHDUniversal definition of myocardial infarctionJ Am Coll Cardiol200750222173219518036459
   PubMed Web of Science ®Google Scholar
• BrenerSJLytleBWSchneiderJPAssociation between CK-MB elevation after percutaneous or surgical revascularization and three-year mortalityJ Am Coll Cardiol200240111961196712475456
   PubMed Web of Science ®Google Scholar
• MukherjeeDOzMPragerRElective coronary revascularization, an iatrogenic form of acute coronary syndrome: how can clinicians reduce the risks?Am Heart J2004148337137715389221
   PubMedGoogle Scholar
• DangasGMehranRFeldmanDPostprocedure creatine kinase-MB elevation and baseline left ventricular dysfunction predict one-year mortality after percutaneous coronary interventionAm J Cardiol200289558658911867045
   PubMedGoogle Scholar
• KugelmassADCohenDJMoscucciMElevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stentingAm J Cardiol19947487487547942542
   PubMed Web of Science ®Google Scholar
• WiviottSDIntensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?Cardiol Clin200826462963718929236
   PubMedGoogle Scholar
• TopolEJToward a new frontier in myocardial reperfusion therapy: emerging platelet preeminenceCirculation19989722112189445175
   PubMedGoogle Scholar
• CollerBSShattilSJThe GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bendBlood200811283011302518840725
   PubMed Web of Science ®Google Scholar
• WiviottSDBraunwaldEAngiolilloDJGreater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38Circulation2008118161626163618757948
   PubMed Web of Science ®Google Scholar
• SchomigANeumannFJKastratiAA randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stentsN Engl J Med199633417108410898598866
   PubMed Web of Science ®Google Scholar
• BertrandMELegrandVBolandJRandomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) studyCirculation19989816159716039778323
   PubMed Web of Science ®Google Scholar
• CutlipDELeonMBHoKKAcute and nine-month clinical outcomes after “suboptimal” coronary stenting: results from the STent Anti-thrombotic Regimen Study (STARS) registryJ Am Coll Cardiol199934369870610483950
   PubMedGoogle Scholar
• JakubowskiJAWintersKJNaganumaHPrasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profileCardiovasc Drug Rev200725435737418078435
   PubMed Web of Science ®Google Scholar
• MichelsonADP2Y12 antagonism: promises and challengesArterioscler Thromb Vasc Biol.2008283s33s3818174449
   PubMedGoogle Scholar
• BertrandMERupprechtHJUrbanPDouble-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS)Circulation2000102662462910931801
   PubMed Web of Science ®Google Scholar
• MehtaSRYusufSPetersRJEffects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE studyLancet2001358928152753311520521
   PubMed Web of Science ®Google Scholar
• SteinhublSRBergerPBMannJT3rdEarly and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trialJAMA2002288192411242012435254
   PubMed Web of Science ®Google Scholar
• SabatineMSCannonCPGibsonCMEffect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY studyJAMA2005294101224123216143698
   PubMed Web of Science ®Google Scholar
• MehtaSRYusufSThe Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular diseaseEur Heart J200021242033204111102254
   PubMed Web of Science ®Google Scholar
• SteinhublSRBergerPBBrennanDMOptimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary interventionJ Am Coll Cardiol200647593994316516075
   PubMed Web of Science ®Google Scholar
• VlaarPJSvilaasTDammanKImpact of pretreatment with clopidogrel on initial patency and outcome in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a systematic reviewCirculation2008118181828183618852370
   PubMed Web of Science ®Google Scholar
• AndersonJLAdamsCDAntmanEMACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency MedicineJ Am Coll Cardiol.2007507e1e15717692738
   PubMed Web of Science ®Google Scholar
• MullerISeyfarthMRudigerSEffect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placementHeart2001851929311119474
   PubMed Web of Science ®Google Scholar
• GurbelPABlidenKPHayesKMThe relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stentingJ Am Coll Cardiol20054591392139615862408
   PubMed Web of Science ®Google Scholar
• PattiGColonnaGPasceriVRandomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) studyCirculation2005111162099210615750189
   PubMed Web of Science ®Google Scholar
• CuissetTFrereCQuiliciJBenefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stentingJ Am Coll Cardiol20064871339134517010792
   PubMed Web of Science ®Google Scholar
• LotrionteMBiondi-ZoccaiGGAgostoniPMeta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary interventionAm J Cardiol200710081199120617920357
   PubMed Web of Science ®Google Scholar
• HochholzerWTrenkDFrundiDTime dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary interventionCirculation2005111202560256415809367
   PubMed Web of Science ®Google Scholar
• von BeckerathNTaubertDPogatsa-MurrayGAbsorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) TrialCirculation2005112192946295016260639
   PubMed Web of Science ®Google Scholar
• MontalescotGSiderisGMeulemanCA randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trialJ Am Coll Cardiol200648593193816949482
   PubMed Web of Science ®Google Scholar
• di SciascioGThe ARMYDA trials (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) at Campus Bio-Medico University: rationale, results and future horizonsFundam Clin Pharmacol.200721Suppl 2414318001321
   PubMedGoogle Scholar
• ColletJPSilvainJLandivierADose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the Reload with Clopidogrel Before Coronary Angioplasty in Subjects Treated Long Term with Dual Antiplatelet Therapy (RELOAD) studyCirculation2008118121225123318765393
   PubMed Web of Science ®Google Scholar
• MehtaSRBassandJPChrolaviciusSDesign and rationale of CURRENT-OASIS 7: a randomized, 2 × 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategyAm Heart J2008156610801088e108119033002
   PubMed Web of Science ®Google Scholar
• HochholzerWTrenkDBestehornHPImpact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placementJ Am Coll Cardiol20064891742175017084243
   PubMed Web of Science ®Google Scholar
• PattiGNuscaAMangiacapraFPoint-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) studyJ Am Coll Cardiol200852141128113318804738
   PubMed Web of Science ®Google Scholar
• MichelsonADPlatelet function testing in cardiovascular diseasesCirculation.200411019e489e49315533872
   PubMed Web of Science ®Google Scholar
• SchwarzURGeigerJWalterUFlow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets – definition and detection of ticlopidine/clopidogrel effectsThromb Haemost19998231145115210494779
   PubMed Web of Science ®Google Scholar
• BarraganPBouvierJLRoquebertPOResistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylationCatheter Cardiovasc Interv200359329530212822144
   PubMed Web of Science ®Google Scholar
• BonelloLCamoin-JauLArquesSAdjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective studyJ Am Coll Cardiol200851141404141118387444
   PubMed Web of Science ®Google Scholar
• SabatineMSHamdallaHNMehtaSREfficacy and safety of clopidogrel pretreatment before percutaneous coronary intervention with and without glycoprotein IIb/IIIa inhibitor useAm Heart J2008155591091718440341
   PubMedGoogle Scholar
• KastratiAMehilliJSchuhlenHA clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrelN Engl J Med2004350323223814724302
   PubMed Web of Science ®Google Scholar
• KastratiAMehilliJNeumannFJAbciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trialJAMA2006295131531153816533938
   PubMed Web of Science ®Google Scholar
• StoneGWMcLaurinBTCoxDABivalirudin for patients with acute coronary syndromesN Engl J Med2006355212203221617124018
   PubMed Web of Science ®Google Scholar
• LincoffAMSteinhublSRManoukianSVChewDPollackCVInfluence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) TrialJ Am Coll Cardiol Intv200816639648
   Google Scholar